FAKTOR-ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 01:13:54 17/05/2024 am IST | ||
| 5.9 EUR | -5.60% |
|
| Current month | -58.22% | ||
| 1 month | -58.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 16/24/16 | 5.9 | -5.60% |
| 15/24/15 | 6.25 | -14.03% |
| 14/24/14 | 7.27 | +0.69% |
| 13/24/13 | 7.22 | -12.80% |
| 10/24/10 | 8.28 | -2.01% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 01:13 am IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK2LTR |
| ISIN | DE000JK2LTR3 |
| Date issued | 23/02/2024 |
| Strike | 503.6 $ |
| Maturity | Unlimited |
| Parity | 10.46 : 1 |
| Emission price | 10.1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.13 € |
|---|---|
| Lowest since issue | 5.9 € |
| Spread | 0.5 € |
| Spread % | 7.90% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
440.6
USD
Average target price
462.6
USD
Spread / Average Target
+4.97%
- Stock Market
- Certificates
- Certificat
